Immunic (IMUX) News Today $0.97 +0.01 (+1.34%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to theMay 19 at 4:38 AM | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Immunic (NASDAQ:IMUX)May 18 at 2:03 AM | americanbankingnews.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayImmunic (NASDAQ:IMUX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-immunic-inc-stock/)May 9, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for ImmunicImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair lifted their FY2025 EPS estimates for Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.86) per share for the year,May 6, 2025 | marketbeat.comLeerink Partnrs Has Bullish Estimate for Immunic Q2 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Immunic in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.16) per share for the quarter, upMay 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Immunic Q1 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair issued their Q1 2025 earnings per share estimates for Immunic in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter anticipates that the company will earn ($0.25) per share for the quMay 4, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday.May 3, 2025 | marketbeat.comImmunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus CalciumMay 2, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday.May 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Industry Conferences in MayMay 2, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. cut its position in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 75.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,398,600 shares of the company's stock after selling 4May 2, 2025 | marketbeat.comImmunic drops after mid-stage trial data for multiple sclerosis drugMay 1, 2025 | msn.comImmunic reports reduced disability worsening in progressive multiple sclerosis trialApril 30, 2025 | proactiveinvestors.comImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER TrialApril 30, 2025 | prnewswire.comImmunic: A Strong Buy With Imminent Data Readout That Should Send Shares HigherApril 28, 2025 | seekingalpha.comOne Immunic Insider Raised Their Stake In The Previous YearApril 25, 2025 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has earned a consensus rating of "Buy" from the eight brokerages that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year pApril 24, 2025 | marketbeat.comEquities Analysts Set Expectations for Immunic Q1 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at B. Riley raised their Q1 2025 EPS estimates for Immunic in a research report issued on Wednesday, April 16th. B. Riley analyst W. Wood now forecasts that the company will post earnings per share of ($0.26) for the quarter, up from theiApril 20, 2025 | marketbeat.comFY2025 Earnings Estimate for Immunic Issued By HC WainwrightImmunic, Inc. (NASDAQ:IMUX - Free Report) - HC Wainwright lifted their FY2025 EPS estimates for shares of Immunic in a research note issued on Tuesday, April 15th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.77) per share for the year, up from theirApril 19, 2025 | marketbeat.comImmunic, Inc. Common Stock (IMUX)April 18, 2025 | nasdaq.comB. Riley Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)B. Riley reissued a "buy" rating and set a $6.00 price target on shares of Immunic in a report on Wednesday.April 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Immunic Q1 Earnings?Immunic, Inc. (NASDAQ:IMUX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Immunic in a note issued to investors on Tuesday, April 15th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.26) per share for the quarter. HC Wainwright currentlyApril 18, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Immunic in a research note on Tuesday.April 17, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)D. Boral Capital restated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Thursday.April 12, 2025 | marketbeat.comEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | prnewswire.comEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic sells 5.67M shares at 90c in registered direct offeringApril 10, 2025 | markets.businessinsider.comImmunic announces pricing of $5.1M direct offering to support clinical pipelineApril 9, 2025 | proactiveinvestors.comImmunic announces pricing of $5.1M direct offering to support clinical pipelineApril 9, 2025 | proactiveinvestors.comImmunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 9, 2025 | prnewswire.comWhat is Leerink Partnrs' Forecast for Immunic Q1 Earnings?Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for Immunic in a report released on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.25) per share fApril 6, 2025 | marketbeat.comImmunic's (IMUX) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a report on Tuesday.April 2, 2025 | marketbeat.comEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1, 2025 | markets.businessinsider.comImmunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1, 2025 | prnewswire.comImmunic (IMUX) Has a New Rating from William BlairMarch 30, 2025 | markets.businessinsider.comWilliam Blair Forecasts Immunic FY2026 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair issued their FY2026 earnings estimates for Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter anticipates that the company will earn ($0.98) per share for the year. WilliamMarch 28, 2025 | marketbeat.comBrokers Set Expectations for Immunic FY2025 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at William Blair issued their FY2025 earnings estimates for shares of Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for theMarch 27, 2025 | marketbeat.comImmunic Sees Unusually High Options Volume (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 2,229 call options on the company. This is an increase of approximately 849% compared to the typical volume of 235 call options.March 26, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Coverage Initiated by Analysts at William BlairWilliam Blair began coverage on Immunic in a research note on Tuesday. They issued an "outperform" rating for the company.March 26, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Immunic (IMUX) with Outperform RecommendationMarch 26, 2025 | msn.comStockNews.com Downgrades Immunic (NASDAQ:IMUX) to SellStockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Thursday.March 20, 2025 | marketbeat.comImmunic management to meet virtually with Piper SandlerMarch 18, 2025 | markets.businessinsider.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to Hold RatingStockNews.com upgraded Immunic from a "sell" rating to a "hold" rating in a report on Wednesday.March 13, 2025 | marketbeat.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Significant Decline in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 2,550,000 shares, a decrease of 32.0% from the January 31st total of 3,750,000 shares. Based on an average daily volume of 933,800 shares, the short-interest ratio is presently 2.7 days.March 3, 2025 | marketbeat.comEQS-News: Immunic to Participate in Scientific and Investor Conferences in MarchMarch 3, 2025 | markets.businessinsider.comImmunic to Participate in Scientific and Investor Conferences in MarchMarch 3, 2025 | prnewswire.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.630.65▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼43▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Benitec Biopharma News Mereo BioPharma Group News Atai Life Sciences News Erasca News Checkpoint Therapeutics News Alpha Teknova News Humacyte News SNDL News Cidara Therapeutics News Olema Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
